Next-generation molecular genetics of brain tumours

Current Opinion in Neurology

Volumn 26, Issue 6, 2013, Pages 681-687

  Suvà, Mario L ^a,b   Louis, David N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Adult gliomas; Medulloblastomas; Meningiomas; Next generation sequencing; Paediatric gliomas

Indexed keywords

SONIC HEDGEHOG PROTEIN;

ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; GLIOBLASTOMA; GLIOMA; HUMAN; MEDULLOBLASTOMA; MENINGIOMA; MOLECULAR GENETICS; OLIGODENDROGLIOMA; REVIEW; WNT SIGNALING PATHWAY; BRAIN NEOPLASMS; GENETICS; MOLECULAR BIOLOGY; PROCEDURES; TRENDS;

BRAIN NEOPLASMS; HUMANS; MOLECULAR BIOLOGY;

EID: 84892373723     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000027     Document Type: Review

References (42)

1. Dunn GP, Rinne ML, Wykosky J, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Develop 2012; 26:756-784.
2. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
3. Camelo-Piragua S, Jansen M, Ganguly A, et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: Chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 2011; 70:110-115.
4. Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade 2 and their consecutive secondary high-grade gliomas. J Neuro-oncol 2012; 108:403-410.
5. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3:709-722.
6. Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 2012; 3:1194-1203.
7. Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012; 124:615-625.
8. Abedalthagafi M, Phillips JJ, Kim GE, et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: A multiinstitutional study of 214 astrocytomas. Mod Pathol 2013. [Epub ahead of print]
9. Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 2013; 125:659-669.
10. Chi AS, Batchelor TT, Yang D, et al. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 2013; 31:e233-e236.
11. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333:1453-1455.
12. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012; 226:7-16.
13. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013; 110:6021-6026.
14. Badiali M, Gleize V, Paris S, et al. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol 2012; 22:841-847.
15. Kim YH, Nonoguchi N, Paulus W, et al. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss. Brain Pathol 2012; 22:834-840.
16. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011; 20:810-817.
17. Parker BC, Annala MJ, Cogdell DE, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013; 123:855-865.
18. Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337:1231-1235.
19. Rheinbay E, Suva ML, Gillespie SM, et al. An aberrant transcription factor network essential for wnt signaling and stem cell maintenance in glioblastoma. Cell Rep 2013; 3:1567-1579.
20. Morris LG, Kaufman AM, Gong Y, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant wnt activation. Nat Genet 2013; 45:253-261.
21. Zhang J, Wu G, Miller CP, et al., St. Jude Children's Research Hospital- Washington University Pediatric Cancer Genome Project. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013; 45:602-612.
22. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482:226-231.
23. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and nonbrainstem glioblastomas. Nat Genet 2012; 44:251-253.
24. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22:425-437.
25. Lewis PW, Muller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013; 340:857-861.
26. Venneti S, Garimella MT, Sullivan LM, et al. Evaluation of histone 3 lysine trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol 2013; 23:558-564.
27. Bjerke L, Mackay A, Nandhabalan M, et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 2013. [Epub ahead of print]
28. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol 2012; 123:473-484.
29. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: The end of the beginning. Nat Rev Cancer 2012; 12:818-834.
30. Dubuc AM, Morrissy AS, Kloosterhof NK, et al. Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathol 2012; 123: 485-499.
31. Jones DT, Jager N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488:100-105.
32. Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488:106-110.
33. Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488:43-48.
34. Dubuc AM, Remke M, Korshunov A, et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol 2013; 125:373-384.
35. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: Clinicopathological correlates of SHH, WNT and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011; 121:381-396.
36. Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013; 45:285-289.
37. Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1 and SMO. Science 2013; 339:1077-1080.
38. Reuss DE, Piro RM, Jones DT, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 2013; 125:351-358.
39. Aavikko M, Li SP, Saarinen S, et al. Loss of SUFU function in familial multiple meningioma. Am J Hum Genet 2012; 91:520-526.
40. Smith MJ, O'Sullivan J, Bhaskar SS, et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 2013; 45:295-298.
41. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013; 339:1567-1570.
42. Louis DN. The next step in brain tumor classification: 'Let us now praise famous men' Or molecules? Acta Neuropathol 2012; 124:761-762.